Evaluating Amiloride for Preventing Migraine Aura
Official title: Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
Run by Centre Hospitalier Universitaire de Nice · NCT04063540 · Data updated 2026-11-12
This study is testing if the medication amiloride can help prevent migraine aura in people who experience this type of migraine.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 5 sites (Bron and 4 other locations) |
| Status | Recruiting |
| Started | August 11, 2020 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT04063540 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with migraine with aura who experience at least one aura episode per month.
✕Probably not a fit
Patients with contraindications to amiloride or those currently on other prophylactic migraine treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the efficacy of amiloride, a non-selective blocker of Acid-Sensing Ion Channel-1, in preventing migraine with aura. It is a randomized crossover trial conducted at three headache centers in France, comparing the effects of amiloride against a placebo. The study aims to provide insights into the therapeutic potential of targeting Acid-Sensing Ion Channels in migraine management. Participants will be monitored for their response to the treatment over a specified period.
Why it matters
Potential benefit: If successful, this study could offer a new preventive treatment option for patients suffering from migraine with aura.
How similar studies have gone: While the approach of targeting Acid-Sensing Ion Channels is relatively novel, preliminary data suggest potential efficacy, but further validation is needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of migraine with aura code * At least 1 aura with aura per month in the 3 months prior to inclusion * No prophylactic antimigraine treatment for at least 1 month prior to inclusion * For women of childbearing age, use of a reliable contraceptive method at least 3 months before and 1 month after the study * Signature of written informed consent * Patient affiliated with Social Security Exclusion Criteria: * Existence of contraindication to taking amiloride: * Known hypersensitivity to the molecule * Hyperkalemia (potassium level (\> 5.5 mmol / l)) * Use of another hyperkalemic diuretic or potassium salts * Renal insufficiency (clearance \<60 ml / min) * Severe hepatocellular insufficiency * In combination with lithium, converting enzyme inhibitors, angiotensin II inhibitors (except if there is hypokalemia), ciclosporin, tacrolimus, non-antiarrhythmic drugs giving torsades de pointes * Cardiovascular and renal history, for subjects over 75 years old * Patient, who from an investigator's point of view would not be compliant to the procedure of the study * Pregnant or lactating patient * Patient under trusteeship, under guardianship, protected by law
Where it's running
-
Ap-Hm
Marly, France Recruiting -
CHU de Montpellier
Montpellier, France Recruiting -
CHU de NICE
Nice, France Recruiting -
Hôpital Pierre Wertheimer
Bron, France Not yet recruiting -
CHU Gabriel Montpied
Clermont-Ferrand, France Not yet recruiting
Study contacts
- Principal investigator: Michel LANTERI-MINET, Dr — Centre Hospitalier Universitaire de Nice
- Study coordinator: Michel LANTERI-MINET, Dr
- Email: lanteri-minet.m@chu-nice.fr
- Phone: 04 92 03 76 46
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gepants for Acute Migraine in the Emergency Department
This study tests whether rimegepant or zavegepant given in the ED can relieve an acute migraine for adults.
-
Neurogenetics and cerebral blood flow in migraine with aura and patent foramen ovale
This project will test whether adults with migraine with aura who have a patent foramen ovale (PFO) differ in specific genes, brain blood flow regulation, or platelet function from those without a PFO.
-
Triggering migraine aura with CGRP
This trial will try giving calcitonin gene-related peptide (CGRP) to adults with migraine with aura to see if it triggers their aura.
-
Analyzing CGRP Levels in Migraine Patients by Age and Sex
This study looks at the levels of a substance linked to migraines in people with migraines and healthy individuals to see how age and sex might affect treatment responses.
-
Evaluating migraine treatment effects using different designs
This study is testing how different ways of giving treatment information affect the effectiveness of a migraine medication compared to a placebo in people with episodic migraines.
-
Evaluating the effectiveness of rimegepant for preventing migraines
This study is testing if taking a new migraine medication called rimegepant every other day can help people with frequent or chronic migraines feel better over two years.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.